SAN DIEGO, Sept. 30, 2014 (GLOBE NEWSWIRE) -- Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis in circulating tumor cell (CTC) and circulating tumor DNA (ctDNA), today announced that Michael Nall, Biocept President and CEO, is scheduled to present a corporate overview at the 13th Annual BIO Investor Forum on October 7, 2014 at The Palace Hotel in San Francisco.
|
Details of the presentation are as follows: |
|
Event: |
13th Annual BIO Investor Forum |
|
Date: |
Tuesday, October 7, 2014 |
|
Time: |
9:30am PT |
|
Place: |
The Palace Hotel (San Francisco, CA) |
About Biocept, Inc.
Biocept, Inc., headquartered in San Diego, California, is a commercial-stage oncology diagnostics company focused on providing information on patients' tumors to physicians using its proprietary technology platform to help improve individual patient treatment. Biocept has developed proprietary technology platforms for capture and analysis of circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) utilizing a standard blood sample to provide physicians with important prognostic and predictive information to enhance individual treatment of their patients with cancer. Biocept currently offers its OncoCEE-BRTM test for breast cancer and plans to introduce tests for lung, colorectal, prostate and other solid tumors based on its proprietary technology platforms.
CONTACT: Investor Contact:
The Ruth Group
David Burke
(646) 536-7009
dburke@theruthgroup.com
